Assays and technologies indicated in these webpages are used by the RBC lab to define pathology and is used to set biomarkers to assess the success in clinical trials.
In addition to commercial instrumentation we have developed unique instruments aimed to resolve specific issues in our assays.
Our services provide support for basic and translational research as well as clinical trials. We assist with design, data collection and assessment of the results with the goal to improve hematology parameters, and blood chemistry.
Assessment of Biomarkers in clinical trials provides insight in the efficacy of the proposed treatment strategies and are in general aimed to show a shift to normalization and include
Hematology assessment using the Advia 2120 hematology analyzer
Oxygen affinity of red blood cells
Plasma biomarkers such as Inflammatory factors, Cell free Hemoglobin, and Heme
Hemoglobin and globin assessment
RBC metabolism including enzyme protein levels and activity as well as intermediates
Cellular markers and morphology assessment using (image) flowcytometry. These assays can be performed on single samples or batched samples and will be invoiced according to the Recharge Rate Schedule.
It is preferred to contact us to discuss specifics of the study and sample collection to optimize results.
In addition to partnerships with academic research we have provided services in the last few years to industry including
- Novo Nordisk (formerly Forma Therapeutics), in their development of Etavopivat to increase oxygen affinity by stimulating PK activity
- Pfizer (formerly Global Blood Therapeutics), using Voxelotor aimed to increase oxygen affinity by hemoglobin modification
- Phoenicia Biosciences to induce hemoglobin F generation
- Cerus, and Hemanext to improve transfusion protocols
- Several academic and industry protocols (CSL Behring, bluebirdbio) aimed to develop gene therapy by altering hemoglobin formation in hematopoietic stem cells